GlassScriptPhysician profile
Sumeet Gupta
NPI 1871971895
$1,409.40
in general payments reported to CMS, 2019-2025
14 companies · $437 in 2025
The $437 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $21.09 · 2021: $130 · 2022: $50.88 · 2023: $595 · 2024: $174 · 2025: $437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,207.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,207.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $371.36 | 2021-2025 | Omni Surgical System, Sion Surgical Instrument |
| Alcon Vision LLC | $293.22 | 2022-2025 | Hydrus Microstent, Clareon, Eysuvis |
| Abbvie INC. | $186.93 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $90.25 | 2023 | Cequa |
| New World Medical,INC. | $88.24 | 2021-2025 | Clearpath, Ahmed Glaucoma Valve, Via360 |
| Glaukos Corporation | $80.11 | 2025 | Idosetr, Istent Infinite |
| Harrow Eye, LLC | $68.69 | 2024-2025 | Vevye |
| Ivantis, INC | $64.21 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $46.06 | 2023 | |
| Allergan, INC. | $42.31 | 2021 | |
| Thea Pharma INC. | $23.57 | 2025 | Iyuzeh |
| Oyster Point Pharma, INC. | $19.94 | 2024 | Ryzumvi, Tyrvaya |
| Bausch & Lomb Americas INC. | $18.17 | 2024 | Vyzulta |
| Ocular Therapeutix, INC. | $16.34 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sumeet Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.